PIK3CA Mutational Status Assessment
ConditionBreast Cancer Metastatic
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorEuropean Institute of Oncology
About this trial
Evaluation of PIK3CA mutational status: a route towards a tailored diagnostic approach.
Eligibility criteria
Qualifiers
Participant has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer by local laboratory.
Participant has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (Fluorescent in situ hybridization (FISH), Chromogenic in situ hybridization (CISH), or Silver-enhanced in situ hybridization (SISH)) test is required by local laboratory testing.
Participants should be at advanced or metastatic setting prior to treatment.
Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
1European Institute of Oncology20141, MilanMI, Italy
Sponsors and collaborators
European Institute of Oncology
Lead sponsor
Source ClinicalTrials.gov